Results
Jubilant Pharmova Q4 FY26 Revenue Up 19% YoY
Jubilant Pharmova reported Q4 FY26 revenue growth of 19% YoY to ₹2,290 Cr, driven by radiopharma, allergy immunotherapy, and CDMO segments.
Full-year FY26 revenue grew 14% to ₹8,280 Cr, though EBITDA
